Nick Turton
Papers
1
Total Citations
22
H-Index
1
About
Nick Turton is a leading figure in the field of high-throughput screening and assay miniaturization, with a primary focus on acoustic droplet ejection (ADE) technology for drug discovery. His most cited work, "Implementation and Challenges of Direct Acoustic Dosing into Cell-Based Assays" (2015, 22 citations), documents the transformative adoption of Labcyte Echo ADE technology at AstraZeneca since 2005. Turton’s contributions center on overcoming the technical hurdles of direct acoustic dosing into cell-based assays, enabling precise, contactless compound transfer that has become the global standard across AstraZeneca’s R&D operations. His research has significantly improved assay reproducibility and throughput, reducing compound consumption and waste. By systematically addressing challenges such as cell viability and assay interference, Turton’s work has accelerated early-stage drug screening, influencing best practices in the pharmaceutical industry. His achievements include spearheading the integration of ADE into routine workflows, a milestone that has shaped modern high-throughput screening methodologies. With a citation count reflecting his foundational role, Turton’s legacy lies in bridging engineering precision with biological assay needs, making him a key innovator in the automation of drug discovery.
Research Focus
Key Achievements
Top Papers
- 1